Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Mochida Intends to Carve Out Market Share with 1st G-Lasta Biosimilar
Mochida Pharmaceutical looks to penetrate the market with its Pegfilgrastim BS, Japan’s first biosimilar version of long-acting G-CSF agent G-Lasta launched last month, by touting the product’s comparability with a cost advantage relative to the original. Pegfilgrastim BS Subcutaneous Injection…
To read the full story
Related Article
- High Demand Triggers Shipment Curb for G-Lasta Biosimilars
March 14, 2024
- 1st G-Lasta Biosimilar Gets Japan Listing, Stelara Follow-On Not on Roster
November 21, 2023
BUSINESS
- Sanofi Delays Japan Launch of Efluelda by One Year, Defers NIP Rollout
July 22, 2026
- Takara Bio to Transfer Cell Processing CDMO Biz to S-RACMO
July 22, 2026
- Takara Bio Voluntary Buyout Draws 148 Employees
July 22, 2026
- Rhythm Pharma Gears Up for First Japan Launch with 50-Strong Team
July 21, 2026
- Fujifilm Toyama Chemical Forms 1st Product-Dedicated Unit for Savyscus
July 21, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…